The clinical trial, sponsored by Ruijin Hospital, aims to evaluate the efficacy and safety of a novel liposomal formulation of Mitoxantrone combined with Azacitidine and Venetoclax in treating secondary AML, AML with extramedullary involvement, and myeloid sarcoma. The targeted patient population is significant, as these conditions often have limited treatment options and poor prognoses. The trial is currently recruiting participants, with an estimated enrollment of 48 patients. If successful, this therapy could capture a niche market within the oncology sector, particularly in regions with high unmet medical needs. The competitive landscape includes existing therapies for AML, but the unique formulation may offer advantages in terms of reduced cardiotoxicity and improved patient outcomes. Diligence should focus on the regulatory pathway, potential market access challenges, and the competitive positioning against established AML treatments.